VÉLIZY-VILLACOUBLAY,
Highlights
(Unaudited, all revenue growth in constant currencies)
- Q4 benefited from large deal activity on both a license and subscription basis
- FY IFRS EPS of
- FY Recurring Revenue up 27% to
- Cash flow from operations up 5% to
- Strong MEDIDATA performance: revenues, customer growth, and backlog for 2021
- DS initiates 2021 non-IFRS financial objectives: total revenue up 9% to 10% at constant currency and EPS of
- UR 4.15, up 13% to 14% at constant currency
.
(C) 2021 M2 COMMUNICATIONS, source